Rising Incidence of Chronic Ailments to Propel Biologics Safety Testing Market

San Francisco, California, June 12, 2018 – The global biologics safety testing market is predicted to exhibit a positive growth trajectory in the coming years, according to recently published report, titled, “Biologics Safety Testing Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2017 – 2025.” The intelligence report discusses how the rapid progress in biotechnology is responsible for biologics safety testing market. Additionally, the report delves into the analysis of various market dynamics, such as opportunities, trends, challenges, and drivers.

Biologics are progressive medications that are used in the treatment of rheumatoid arthritis, cancer, and other diseases. Biologics typically comprise of large molecules like recombinant proteins, monoclonal antibodies and some other major diseases. It is important to perform regular quality checks on such medicines as these drugs could prove to have substantial effect on the patient’s body. It is vital to determine the safety of these drugs during their manufacture. This is leading to the emergence of biologics safety testing market to a large extent.

The key factors responsible for the rise of the global biologics safety testing market are the increasing prevalence of chronic ailments such as diabetes, cancer, and arthritis, increased demand for specialized therapies, and rapid progress in biologics and pharmaceuticals. Additionally, increased interest demonstrated by government towards overall healthcare by implementation of safety and quality checks is further fuelling the growth of the global biologics safety testing market.

Get Sample Copy of this Report @


Geography-wise, North America held a key share of the global market in 2016, and is expected to continue holding a prominent position in the biologics safety testing market in the coming years. At the same time, Asia Pacific is predicted to exhibit high potential for growth over the coming years on account of the presence of briskly developing economies such as China and India. The countries comprise of a large population, with rapid developments in their pharmaceutical, biotechnology and outsourcing sectors.

Key players operating in the global biologics safety testing market are Eurofins Scientific Se, Pace Analytical Services Inc., Wuxi Apptec, Charles River Laboratories International, Inc., and Thermo Fisher Scientific Inc.